Voyager Therapeutics Inc.’s stock VYGR soared 32% early Tuesday, following the announcement of a new license agreement with Novartis Pharma AG, a unit of Novartis AG NVS. The collaboration aims to advance potential gene therapies for Huntington’s disease and spinal muscular atrophy. As part of the agreement, Voyager will grant Novartis access to its Tracer capsids and other intellectual property.
Significant Financial Benefits
The deal brings Voyager an upfront payment of $100 million, which includes $20 million for newly issued equity. Additionally, Voyager stands to receive up to $1.2 billion in milestones related to preclinical development, regulatory approvals, and sales achievements. Furthermore, Voyager will be entitled to tiered royalties on global net sales of products that are developed using its technology.
Under the terms of the agreement, Voyager will be responsible for advancing the preclinical aspects of the project, while Novartis will take charge of all clinical development and commercialization efforts for the Huntington’s disease program.
Voyager Therapeutics Inc.’s stock has demonstrated impressive growth over the past 12 months, with a 38% increase. In comparison, the S&P 500 has only gained 24% during the same period.
Stay tuned for more updates on Voyager Therapeutics Inc.’s groundbreaking collaboration with Novartis Pharma AG in the field of gene therapies for Huntington’s disease and spinal muscular atrophy.